South Korea’s Financial Services Commission will revise its regulatory system in July to allow local banks to operate nonfinancial services like food delivery via their mobile applications.
The country's top financial regulator will also enable financial entities, including banks, brokerages, and credit card operators, to set up “open banking” services, where customers can manage accounts at multiple financial entities by using a single mobile financial application.
Discussions and research are underway to expand the businesses in the finance sector.
The FSC will also implement emergency loan programs worth 3 trillion won for small merchants, who have were affected by the government’s ban on private gatherings of five or more people.
Maximum lending rates will also be reduced from 24 to 20 percent per annum starting February next year, which would ease financial burdens on pandemic-hit debtors.


Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Google Secures Pentagon AI Deal for Classified Projects
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



